Market closedNon-fractional

Cardiff Oncology/CRDF

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cardiff Oncology

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Ticker

CRDF

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

-

Cardiff Oncology Metrics

BasicAdvanced
$101M
Market cap
-
P/E ratio
-$0.90
EPS
1.88
Beta
-
Dividend rate
$101M
1.88
5.91
5.706
2.136
3.279
-30.66%
-51.12%
164.799
1.64
1.64
-3.283
54.43%
1.63%
18.13%
1.74%

What the Analysts think about Cardiff Oncology

Analyst Ratings

Majority rating from 4 analysts.
Buy

Cardiff Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,000.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
100.00%
Net income
-$10M
7.53%
Profit margin
-5,000.00%
-46.24%

Cardiff Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.25
-$0.22
-$0.21
-$0.22
-
Expected
-$0.26
-$0.29
-$0.28
-$0.25
-$0.25
Surprise
-3.55%
-22.81%
-24.32%
-11.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cardiff Oncology stock?

Cardiff Oncology (CRDF) has a market cap of $101M as of July 06, 2024.

What is the P/E ratio for Cardiff Oncology stock?

The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of July 06, 2024.

Does Cardiff Oncology stock pay dividends?

No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cardiff Oncology dividend payment date?

Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.

What is the beta indicator for Cardiff Oncology?

Cardiff Oncology (CRDF) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Cardiff Oncology stock

Buy or sell Cardiff Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing